Evidence-based pancreatology: what do we know about chronic pancreatitis by 2020?
PDF (Русский)
DOCX (Українська)

Keywords

pancreas, chronic pancreatitis, exocrine pancreatic insufficiency, diagnostics, treatment

How to Cite

Gubergrits, N. B., Byelyayeva, N. V., Lukashevich, G. M., Fomenko, P. G., Berezhnaya, E. V., & Rakhmetova, V. S. (2020). Evidence-based pancreatology: what do we know about chronic pancreatitis by 2020?. Herald of Pancreatic Club, 47(2), 19-31. https://doi.org/10.33149/vkp.2020.02.02

Abstract views: 49
PDF Downloads: 20 PDF Downloads: 0

Abstract

The article reveals the achievements of modern pancreatology in the field of pathogenesis, dynamics of development and treatment of chronic pancreatitis (CP). Data of genetic studies describing the most diverse genetic mutations predisposing to the appearance of CP are considered. Genetic mutations causing not only СP, but also pancreatic cancer are analyzed. Risk factors of autoimmune pancreatitis development are mentioned; features of accompanying kidney affection are described. СP conceptual model including the phase of early СP is presented. The provisions of the International Consensus on Early CP are given, the criteria for diagnosing this stage of СP using both clinical/functional criteria and visualizing research methods are listed. Pathophysiological features of pancreatic fibrogenesis are considered. The results of studies describing the peculiarities of the appearance of exocrine pancreatic insufficiency (EPI), the feasibility of determining fecal elastase-1 as a screening of EPI are analyzed. Peculiarities of EPI occurrence in osteopenia, cardiovascular disease are considered. The nuances of pancreatic enzyme replacement therapy (PERT) in the pancreatic steatosis, obesity are described, as well as its impact on the quality of life of patients with CP and EPI. Advantages of using the enteric-coated minimicrospheres and possibility of controlling the clinical manifestations of EPI, increasing body weight, improving quality of life and its duration of PERT are listed. Optimal doses of enzyme preparations during PERT are considered, results of randomized studies proving the efficacy of minimicrospherical preparations are given.

https://doi.org/10.33149/vkp.2020.02.02
PDF (Русский)
DOCX (Українська)

References

1. Мудрые мысли о медицине и врачевании: изречения, афоризмы, цитаты. Авт. композиции Я. С. Циммерман. ГЭОТАР-Медиа. 2015: 256.
2. Apte M., Pirola R., Wilson J. Pancreatic stellate cell: physiologic role, role in fibrosis and cancer. Curr. Opin. Gastroenterol. 2015. Vol. 31. P. 416–423.
3. Bang U. C., Benfield T., Hyldstrup L. et al. Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology. 2014. Vol. 146(4). P. 989–994.
4. Barkin J. A., Barkin J. S. Chronic pancreatitis and bone disease. J. Clin. Densitom. 2019. Vol. S1094–6950(19). Р. 30125–30128.
5. Birari R., Bhutani K. Pancreatic lipase inhibitors from natural sources. P. Unexplored potential. Drug Discov. 2007. Vol. 12. P. 879–889.
6. Brennan G. T., Saif M. W. Pancreatic enzyme replacement therapy: a concise review. JOP. 2019. Vol. 20, No 5. P. 121–125.
7. Cohn J. A., Friedman K. J., Noone P. G., Knowles M. R. et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N. Engl. J. Med. 1998. Vol. 339. P. 653–658.
8. Czako L., Takacs T., Hegyi P. et al. Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis. Can. J. Gastroenterol. 2003. Vol. 17, No 10. P. 597–603.
9. D’Haese J. G., Ceyhan G. O., Demir I. E. et al. Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life. Pancreas. 2014. Vol. 43, No 6. P. 834–841.
10. de la Iglesia-Garcia D., Vallejo-Senra N., Iglesias-Garcia J. et al. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis. J. Clin. Gastroenterol. 2018. Vol. 52, No 8. P. e63–e72.
11. de Martines D., Gianotten S., Wetzels J., van der Meijden W. Secondary hyperoxaluria due to pancreatic insufficiency. The Netherlands Journal of Medicine. 2019. Vol. 77, No 8. P. 287–292.
12. Dominguez-Munoz J. Management of pancreatic exocrine insufficiency. Curr. Opin. Gastroenterol. 2019. Vol. 35, No 5. P. 455–459.
13. Felderbauer P., Hoffmann P., Einwachter H., Bulut K., Ansorge N. et al. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol. 2003. Vol. 3. P. 34.
14. Fjeld K., Weiss F. U., Lasher D., Rosendahl J., Chen J. M., Johansson B. B. et al. A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis. Nat. Genet. 2015. Vol. 47. P. 518–522.
15. Frost F., Kacprowski T., Rühlemann M., Bülow R., Kühn J. et al. Impaired exocrine pancreatic function associates with changes in intestinal microbiota composition and diversity. Gastroenterology. 2019. Vol. 156, No 4. P. 1010–1015.
16. Gómez J., Molero X., Vaquero E., Alonso A., Salas A. et al. Vitamin E attenuates biochemical and morphological features associated with development of chronic pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2004. Vol. 287, No 1. P. G162– G169.
17. Gubergrits N., Malecka-Panas E., Lehman G. A. et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment. Pharmacol. Ther. 2011. Vol. 33, No 10. P. 1152–1161.
18. Hohwieler M., Illing A., Hermann P. et al. Human pluripotent stem cell derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut. 2017. Vol. 66. P. 473–486.
19. Huang W., Iglesia-García D., Baston-Rey I., Calviño-Suarez C., Lariño‑Noia J. et al. Exocrine pancreatic insufficiency following acute pancreatitis: systematic review and meta-analysis. Digestive Diseases and Sciences. 2019. Vol. 64. P. 1985–2005.
20. Ito K., Matsuura K., Mihara Y. et al. Delivery of pancreatic digestive enzymes into the gastrointestinal tract by pancreatic exocrine tissue transplant. Sci. Rep. 2019. Vol. 9. P. 5922.
21. Ito T., Ishiguro H., Ohara H., Kamisawa T., Sakagami J. et al. Evidence based clinical practice guidelines for chronic pancreatitis 2015. J. Gastroenterol. 2016. Vol. 51, No 2. P. 85–92.
22. Ito T., Kataoka K., Irisawa A., Hirota M., Miyakawa H. et al. Prospective follow-up study of the patients with early CP or possible CP (The final report of the RCIPD chaired by Shimosegawa T). The RCIPD Report. 2015. P. 145e9.
23. Kleeff J., Whitcomb D. C., Shimosegawa T., Esposito I., Lerch M. M. et al. Chronic pancreatitis. Nat. Rev. Dis. Primers. 2017. Vol. 3. P. 17060.
24. Kume K., Masamune A., Ariga H., Shimosegawa T. Alcohol consumption and the risk for developing pancreatitis: a case-control study in Japan. Pancreas. 2015. Vol. 44. P. 53–58.
25. Kuno A., Yamada T., Masuda K., Ogawa K., Sogawa M. et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology. 2003. Vol. 124, No 4. P. 1010–1019.
26. Layer P, Kashirskaya N, Gubergrits N. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. World J. Gastroenterol. 2019. Vol. 25, No 20. P. 2430–2441.
27. Lin Y., Tamakoshi A., Hayakawa T., Ogawa M., Ohno Y. Cigarette smoking as a risk factor for chronic pancreatitis: a case-control study in Japan. Research Committee on Intractable Pancreatic Diseases. Pancreas. 2000. Vol. 21. P. 109–114.
28. Löhr J. M., Domínguez-Muñoz E., Rosendahl J. et al. United European Gastroenterology evidence based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterology Journal. 2017. Vol. 5, No 2. P. 153–199.
29. Lowenfels A., Maisonneuve P., Cavallini G., Ammann R. W., Lankisch P. G. et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. Engl. J. Med. 1993. Vol. 328. P. 1433–1437.
30. Masamune A., Nakano E., Hamada S., Kakuta Y., Kume K., Shimosegawa T. Common variants at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with chronic pancreatitis in Japan. Gut. 2015. Vol. 64. P. 1345–1346.
31. Masamune A., Nakano E., Kume K., Kakuta Y., Ariga H., Shimosegawa T. Identification of novel missense CTRC variants in Japanese patients with chronic pancreatitis. Gut. 2013. Vol. 62. P. 653–654.
32. Motoo Y. Antiproteases in the treatment of chronic pancreatitis. JOP. 2007. Vol. 9, No 4. P. 533¬537.
33. Nagashio Y., Ueno H., Imamura M., Asaumi H., Watanabe S. et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice. Lab. Invest. 2004. Vol. 84, No 12. P. 1610–1618.
34. Nikolic S., Dugic A., Steiner C., Tsolakis A., Löfman I. et al. Chronic pancreatitis and the heart disease. P. Still terra incognita? World J. Gastroenterol. 2019. Vol. 25, No 44. P. 6561¬6570.
35. Pei Y., Ai T., Deng Z., Wu D., Liang H. et al. Impact of plant extract on the gastrointestinal fate of nutraceutical-loaded nano emulsions: Phytic acid inhibits lipid digestion but enhances curcumin bio accessibility. Food Funct. 2019. Vol. 10. P. 3344–3355.
36. Ramesh H., Reddy N., Bhatia S. et al. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40 000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Pancreatology. 2013. Vol. 13, No 2. P. 133–139.
37. Reding T., Bimmler D., Perren A., Sun L., Fortunato F. et al. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut. 2006. Vol. 55, No 8. P. 1165–1173.
38. Ribichini E., Stigliano S., Rossi S., Zaccari P., Sacchi M., Bruno G. et al. Role of fibre in nutritional management of pancreatic diseases. Nutrients. 2019. Vol. 11. P. 2219.
39. Rosendahl J., Witt H., Szmola R., Bhatia E., Ozsvari B. et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat. Genet. 2008. Vol. 40. P. 78–82.
40. Safdi M., Bekal P. K., Martin S. et al. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas. 2006. Vol. 33, No 2. P. 156–162.
41. Satouchi K., Matsushita S. Purification and properties of a lipase inhibiting protein from soy bean cotyledons. Agric. Biol. Chem. 1976. Vol. 40. P. 889–897.
42. Sharer N., Schwarz M., Malone G., Howarth A., Painter J. et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N. Engl. J. Med. 1998. Vol. 339. P. 645–652.
43. Shimizu K., Shiratori K., Kobayashi M., Kawamata H. Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. Pancreas. 2004. Vol. 29, No 1. P. 67–74.
44. Shimosegawa T. A new insight into chronic pancreatitis. Tohoku J. Exp. Med. 2019. Vol. 248. P. 225–238.
45. Shobassy M., Husainat N., Tabash A., Patel K., El-Serag H. et al. Endoscopic ultrasound findings in patients diagnosed with exocrine pancreatic insufficiency by low fecal elastase-1. Gastroenterology Research and Practice. 2019. P. 5.
46. Singh G., Suresh S., Bayineni V., Kadeppagari R. Lipase inhibitors from plants and their medical applications. Int. J. Pharm. Pharm. Sci. 2015. Vol. 7. P. 1–5.
47. Szmola R., Sahin-Tóth M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht’s enzyme Y. Proc. Natl. Acad. Sci. 2007. Vol. 104. P. 11227–11232.
48. Tahtacı M., Algın O., Karakan T., Yürekli Ö., Alışık M. et al. Can pancreatic steatosis affect exocrine functions of pancreas? Turk. J. Gastroenterol. 2018. Vol. 29. P. 588–594.
49. The pancreas: an integrated textbook of basic science, medicine and surgery / Eds. H. G. Beger, A. L. Warshaw, R. H. Hruban et al. Oxford. P. Willey Blackwell. 2018. P. 1173.
50. Thorat V., Reddy N., Bhatia S. et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40 000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis — a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2012. Vol. 36, No 5. P. 426–436.
51. Toskes P. et al. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. Pancreas. 2011. Vol. 40, No 3. P. 376–382.
52. Ueda J., Tanaka M., Ohtsuka T., Tokunaga S., Shimosegawa T. Research Committee of Intractable Diseases of the Pancreas. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. Surgery. 2013. Vol. 153. P. 357–364.
53. Vallejo-Senra N., De la Inglesia-Garcia D., Lopez-Lopez A. et al. Cardiovascular risk (CVR) associated with pancreatic exocrine insufficiency (PEI) in patients with chronic pancreatitis (CP). 48th European Pancreatic Club (EPC) meeting. Pancreatology. 2016. Vol. 16, No 3S1. P. S80.
54. van Westerloo D., Florquin S., de Boer A., Daalhuisen J., de Vos A. et al. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J. Pathol. 2005. Vol. 166, No 3. P. 721–728.
55. Vujasinovic M., Hedström A., Maisonneuve P., Valente R., von Horn H. et al. Zinc deficiency in patients with chronic pancreatitis. World J. Gastroenterol. 2019. Vol. 25, No 5. P. 600–607.
56. Vujasinovic M., Kunst G., Breznikar B., Rozej B., Tepes B. Is pancreatic exocrine insufficiency a cause of malabsorption in patients after bariatric surgery? JOP. 2016. Vol. 17. P. 241–244.
57. Vujasinovic M., Pozzi Mucelli R., Valente R., Verbeke C., Haas S. L, Löhr J. Kidney involvement in patients with type 1 autoimmune pancreatitis. J. Clin. Med. 2019. Vol. 18, No 2. P. E258.
58. Vujasinovic M., Valente R., Maier P., von Beckerath V., Haas S. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. Pancreatology. 2018. Vol. 18, No 8. P. 900–904.
59. Vujasinovic M., Valente R., Thorel A., Rutkowski W., Haas S. et al. Pancreatic exocrine insufficiency after bariatric surgery. Nutrients. 2017. Vol. 9. P. 1241.
60. Whitcomb D. C., Frulloni L., Garg P. et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016. Vol. 16, No 2. P. 218–224.
61. Whitcomb D. C., Lehman G. A., Vasileva G. et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am. J. Gastroenterol. 2010. Vol. 105(10). P 2276–2286.
62. Whitcomb D. C., Shimosegawa T., Chari S. T. et al. International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, Pancreas. Fest Working Group and European Pancreatic Club. Pancreatology. 2018. Vol. 18. P. 516–527.
63. Whitcomb D. C., Gorry M. C., Preston R. A., Furey W., Sossenheimer M. et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat. Genet. 1996. Vol. 14. P. 141–145.
64. Whitcomb D. C., La Rusch J., Krasinskas A. M., Klei L., Smith J. P. et al. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat. Genet. 2012. Vol. 44. P. 1349–1354.
65. Whitcomb D. C., Preston R. A., Aston C. E., Sossenheimer M. J., Barua P. S. et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology. 1996. Vol. 110. P. 1975–1980.
66. Winny M., Paroglou V., Bektas H. et al. Insulin dependence and pancreatic enzyme replacement therapy are independent prognostic factors for long-term survival after operation for chronic pancreatitis. Surgery. 2014. Vol. 155, No 2. P. 271–279.
67. Witt H., Beer S., Rosendahl J., Chen J. M., Chandak G. R. et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat. Genet. 2013. Vol. 45. P. 1216–1220.
68. Witt H., Luck W., Hennies H. C., Classen M., Kage A. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat. Genet. 2000. Vol. 25. P. 213–216.
69. Yamada T., Kuno A., Masuda K., Ogawa K., Sogawa M. et al. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J. Pharmacol. Exp. Ther. 2003. Vol. 307, No 1. P. 17–23.
70. Zha M., Xu W., Jones P. et al. Isolation and characterization of human islet stellate cells. Exp. Cell Res. 2016. Vol. 314. P. 61–66.
71. Zhang Y., Cui L., Fang F. Chronic high-fat diets induce oxide injuries and fibrogenesis of pancreatic cells in Rats X. 42nd European Pancreatic Club (EPC) meeting. Pancreatology. 2010. Vol. 10. P. 273.
72. Zheng Q., Koike K., Han L., Okuda H., Nikaido T. New biologically active triterpenoid saponins from Scabiosa tschiliensis. J. Nat. Prod. 2004. Vol. 67. P. 604-613.
73. Zou W. B., Boulling A., Masamune A., Issarapu P., Masson E. et al. No association between CEL-HYB hybrid allele and chronic pancreatitis in Asian populations. Gastroenterology. 2016. Vol. 150. P. 1558–1560.